Drug has higher selectivity for PARP1, improving safety and tolerability SAN DIEGO – Saruparib, a selective inhibitor of poly-ADP...
SAN DIEGO – A combination of the KRASG12C inhibitor adagrasib (Krazati) and the anti-epidermal growth factor receptor (EGFR) antibody...
The investigational therapy uses a cold-temperature probe to kill a portion of prostate cancer cells and release tumor-specific neoantigens...
SAN DIEGO – Of the 46 cancer drugs that the U.S. Food and Drug Administration (FDA) granted accelerated approval...
SAN DIEGO – Accelerated aging was more common in recent birth cohorts and was associated with increased incidence of...
Results are from a median follow-up of three years SAN DIEGO – An adjuvant treatment regimen that included autogene...
SAN DIEGO – The PD-1/CTLA-4 bispecific antibody cadonilimab plus chemotherapy improved progression-free survival and overall survival in patients with...
PHILADELPHIA — The American Association for Cancer Research (AACR) today announced its newest class of grant recipients. Since 1993, the AACR...
The American Association for Cancer Research (AACR) will honor Pfizer Inc., as well as Pfizer’s chairman and chief executive...
Among patients over 65 who received an allogeneic hematopoietic stem cell transplant (allo-HCT) for the treatment of acute myeloid...